Pyrrolobenzodiazepines

US9399073B2 · kind B2 · utility

Assignees

• SEATTLE GENETICS, INC. · US
• MedImmune Limited · US

Inventors

• Philip Wilson Howard · London, GB
• Arnaud Tiberghien · London, GB
• Scott Jeffrey · Bothell, US
• Patrick Burke · Bothell, US

Key dates

• Filing date: Oct 12, 2012
• Grant date: Jul 26, 2016
• Expiry date: Oct 12, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H15/22
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound with the formula (I), wherein: R2 is of formula (II), where X is selected from the group comprising: OH, SH, CO2H, COH, N═C═O, NHNH2, CONHNH2, formula (A), formula (B), NHRN, wherein RN is selected from the group comprising H and C1-4 alkyl; RC1, RC2 and RC3 are independently selected from H and unsubstituted C1-2 alkyl; and either: R12 is selected from the group consisting of: (ia) C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene; (ib) C1-5 saturated aliphatic alkyl; (ic) C3-6 saturated cycloalkyl; (id) formula (C), wherein each of R21, R22 and R23 are independently selected from H, C1-3 saturated alkyl, C2-3 alkenyl, C2-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R12 group is no more than 5; (ie) formula (D), wherein one of R25a and R25b is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and (if) formula (E), where R24 is selected from: H; C1-3 saturated alkyl; C2-3 alkenyl; C2-3 alkynyl; cyclopropyl…